Xinhua Finance and Economics, Shanghai, November 9 (Reporter Du Kang) - Geely Science, a leading global biopharmaceutical company, has embarked on its second "journey to enter the international market" this year. From the "first time customer" who participated in the exhibition last year to the "repeat customer" who went to the CIIE again this year, Geely Science witnessed the rapid launch of drugs on display and witnessed the spillover effects brought by the CIIE. Geely Science stated that it looks forward to further expanding its "circle of friends" in China with the help of "Jinbo Magnetic Force".
In 2017, Geely officially began commercial operations in China, with drugs covering viral hepatitis, HIV prevention and treatment, as well as antifungal infections and tumors. At present, eleven innovative drugs have been approved in China, of which eight have been included in the national medical insurance catalog.
Jin Fangqian, Global Vice President and General Manager of Geely Science in China, said, "Last year, Geely participated for the first time and witnessed the spillover effects brought by the CIIE. We have personally witnessed the rapid launch of drugs on display. This year, when we go to CIIE again, we look forward to sharing Geely's rapid development and future plans in China with all sectors of society on such an open platform, accelerating the introduction of innovative products and continuously improving drug accessibility
It is worth mentioning that the innovative drug Tuodawei& Reg; And products in the field of antifungal agents, Anbisoft& Reg; Two drugs were first exhibited at the CIIE last year and have been successfully launched in China this year, rapidly achieving patient accessibility. This year's CIIE, Geely China comprehensively presented its "star" innovative drugs in the fields of HIV prevention and treatment, viral hepatitis, tumors, and antifungal agents.
In 2022, Gilead launched the construction of local research and development team and research and development capacity in China. In less than a year, it has promoted the rapid development of 14 Phase II/III clinical research projects, including 11 Phase II/III tumor clinical studies covering breast cancer, lung cancer, urogenital tumors, digestive tract tumors and gynecological tumors, and 3 anti-virus Phase III clinical studies. In addition, Geely also demonstrated plans to introduce innovative product indications for clinical research in China.
Thanks to the favorable policies of the country in promoting high-quality development and encouraging innovation, Geely has achieved rapid development since entering China for six years. "Jin Fangqian stated that China is one of Geely's three important strategic markets globally. Looking forward to further expanding the "circle of friends" of the medical ecosystem in China through the "Jinbo Magnetic Force".
The reporter learned that Geely will sign a series of contracts with China's ecological partners in the future, including signing a strategic cooperation memorandum with Jinyu Medical to assist in early diagnosis, treatment, and standardized treatment of diseases; Signed strategic cooperation memorandums with Shulan (Hangzhou) Hospital and Tunchang Branch of Hainan Provincial People's Hospital to support the prevention and treatment of viral hepatitis in Hangzhou and Hainan; Signed strategic cooperation with the Hainan Boao Lecheng International Medical Tourism Pilot Zone Management Bureau and Sichuan University West China Lecheng Hospital to promote the pilot trial of innovative drugs in the field of cancer in Boao.